Artwork

内容由Karen Jagoda提供。所有播客内容(包括剧集、图形和播客描述)均由 Karen Jagoda 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Multiplexed Diagnostic Test for Detecting Levels of Multiple Antibodies with Dr. Tadd Lazarus Pictor TRANSCRIPT

 
分享
 

Manage episode 352150366 series 99915
内容由Karen Jagoda提供。所有播客内容(包括剧集、图形和播客描述)均由 Karen Jagoda 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Dr. Tadd Lazarus is the Chief Medical Officer at Pictor, working on innovative diagnostic tests to provide answers to complicated clinical questions concerning the status of a patient's level of antibodies. From one specimen, their test can determine if the antibodies have been produced as a result of vaccinations or boosters and if the patient had the disease being tested for. Their mission is to help patients determine if they have effective antibody levels and are able to have the kind of response that will be protected them over time.

Tadd explains, "We develop innovative diagnostic solutions to enable more informed clinical decisions both in human and animal health. Specifically, we have a highly multiplexed platform that really changes the way antibodies are detected. As we know from COVID, antibodies are proteins that our body manufactures in response to infectious agents, except we detect them differently. We detect antibodies in an incredibly focused and what we call highly multiplexed manner, so that we have an incredibly sensitive and specific test. But moreover, it's able to detect multiple antibodies that the body produces for multiple infectious agents at one time. That's a very big change."

"One of the reasons why it is important to determine if vaccinations and boosters are effective is that there are antibodies that can be administered to patients intravenously if those patients are determined not to have a clinically significant antibody response to vaccinations/boosters and/or infection. And those formulations are getting tweaked now for more predominant strains, so making sure that they're covered. So there's something that we can do about that for the immunosuppressed, the elderly, and the immunocompromised, who are not showing a healthy and protective antibody response."

@PictorLtd #pictor #PictArray #IVD #Biotech #Innovative #HumanHealth #COVID #Antibodies #AntibodyTest #ImmuneSystem

PictorDX.com

Listen to the podcast here

  continue reading

1725集单集

Artwork
icon分享
 
Manage episode 352150366 series 99915
内容由Karen Jagoda提供。所有播客内容(包括剧集、图形和播客描述)均由 Karen Jagoda 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Dr. Tadd Lazarus is the Chief Medical Officer at Pictor, working on innovative diagnostic tests to provide answers to complicated clinical questions concerning the status of a patient's level of antibodies. From one specimen, their test can determine if the antibodies have been produced as a result of vaccinations or boosters and if the patient had the disease being tested for. Their mission is to help patients determine if they have effective antibody levels and are able to have the kind of response that will be protected them over time.

Tadd explains, "We develop innovative diagnostic solutions to enable more informed clinical decisions both in human and animal health. Specifically, we have a highly multiplexed platform that really changes the way antibodies are detected. As we know from COVID, antibodies are proteins that our body manufactures in response to infectious agents, except we detect them differently. We detect antibodies in an incredibly focused and what we call highly multiplexed manner, so that we have an incredibly sensitive and specific test. But moreover, it's able to detect multiple antibodies that the body produces for multiple infectious agents at one time. That's a very big change."

"One of the reasons why it is important to determine if vaccinations and boosters are effective is that there are antibodies that can be administered to patients intravenously if those patients are determined not to have a clinically significant antibody response to vaccinations/boosters and/or infection. And those formulations are getting tweaked now for more predominant strains, so making sure that they're covered. So there's something that we can do about that for the immunosuppressed, the elderly, and the immunocompromised, who are not showing a healthy and protective antibody response."

@PictorLtd #pictor #PictArray #IVD #Biotech #Innovative #HumanHealth #COVID #Antibodies #AntibodyTest #ImmuneSystem

PictorDX.com

Listen to the podcast here

  continue reading

1725集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南